| Symbol | ALLR |
|---|---|
| Name | ALLARITY THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 123 E TARPON AVE, TARPON SPRINGS, Florida, 34689, United States |
| Telephone | +1 401 - 426-4664 |
| Fax | — |
| — | |
| Website | https://www.allarity.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001860657 |
| Description | Allarity Therapeutics Inc is a clinical-stage, precision medicine company. Additional info from NASDAQ: |
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
Read more(90% Positive) ALLARITY THERAPEUTICS, INC. (ALLR) Provides Update on step for Allarity
Read moreAllarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
Read more(90% Positive) ALLARITY THERAPEUTICS, INC. (ALLR) Announces Enrollment Update for observed Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreAllarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
Read moreAllarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
Read more(99% Neutral) ALLARITY THERAPEUTICS, INC. (ALLR) Reports Q2 2026 Financial Results
Read moreAllarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
Read moreAllarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
Read moreJensen Thomas 🟢 acquired 200.0K shares of Allarity Therapeutics, Inc. (ALLR) Transaction Date: Jan 28, 2026 | Filing ID: 056373
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05571969 | Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patie… | Phase1 | Advanced Solid Tumors | Terminated | 2023-03-08 | 2024-10-07 | ClinicalTrials.gov |
| NCT04796324 | Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by … | Phase2 | Metastatic Breast Cancer | Terminated | 2021-03-01 | 2025-11-01 | ClinicalTrials.gov |
| NCT03878849 | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Ad… | Phase2 | Advanced Ovarian Cancer | Recruiting | 2019-04-15 | 2027-09-01 | ClinicalTrials.gov |
| NCT03877796 | Clinical Pre-screening Protocol for Ovarian Cancer | — | Ovarian Cancer | Recruiting | 2019-04-11 | 2027-12-01 | ClinicalTrials.gov |
| NCT03562832 | Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-1… | Phase2 | Metastatic Breast Cancer | Completed | 2018-06-20 | 2024-08-01 | ClinicalTrials.gov |
| NCT03196947 | Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Mu… | Phase1 | Relapsed/Refractory Multiple Myeloma | Terminated | 2017-06-13 | 2020-01-16 | ClinicalTrials.gov |
| NCT01861496 | Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patient… | Phase1 | Phase 1: Advanced or Refractory Solid Tumours | Completed | 2013-04-01 | 2021-10-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Drug Response Predictor® (DRP) | Drug | Preclinical | Ovarian Cancer | RECRUITING | NCT03877796 |
| 2X-121 + 500 mg dovitinib | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT05571969 |
| 2X-121 + 400 mg dovitinib | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT05571969 |
| 2X-121 + 300 mg dovitinib | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT05571969 |
| 2X-121 1000 mg | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT05571969 |
| 2X-121 800 mg | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT05571969 |
| 2X-121 600 mg | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT05571969 |
| APO010 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT03196947 |
| LiPlaCis | Other | Phase PHASE1 | Phase 1: Advanced or Refractory Solid Tumours | COMPLETED | NCT01861496 |
| PARP inhibitor 2X-121 | Other | Phase PHASE2 | Metastatic Breast Cancer | COMPLETED | NCT03562832 |
| 2X-121 and dovitinib | Other | Phase PHASE1 | Advanced Solid Tumors | SUSPENDED | NCT05571969 |
| 2X-121 | Other | Phase PHASE2 | Advanced Ovarian Cancer | RECRUITING | NCT03878849 |
| Drug Response Predictor® (DRP) | Drug | Preclinical | Ovarian Cancer | RECRUITING | NCT03877796 |
| Ixabepilone Injection | Other | Phase PHASE2 | Metastatic Breast Cancer | TERMINATED | NCT04796324 |